Monitoring the progression or regression of intraabdominal metastatic disease is required for knowledgeable management of chemotherapeutic regimens designed to treat metastases. Computerized tomography (CT) and CT with EOE‐13, a liver contrast agent, allowed precise measurement of metastatic disease. The tumor doubling time of colorectal metastases in four patients was determined from serial CT scans of individual patients. Tumor doubling times of untreated patients varied from 50 to 95 days, and were in the same range for hepatic, lymph node, or intraperitoneal metastatic disease. These data may indicate that metastatic disease of colorectal cancer progresses at a faster rate in the peritoneal cavity than is reported for colorectal cancer metastatic to the lungs. The response to chemotherapy or progression of disease was also determined in treated patients. High resolution CT scanning with EOE‐13 allowed calculation of tumor doubling times, and therefore more precise management of cancer patients with metastases.
F1 lymphocytes stimulated in vitro by parental cells were evaluated for cytotoxicity against semisyngeneic tumors and lymphoblasts. B6AF1 (H-2a,b) spleen cells were placed in culture with C57BL/6 (H-2b) or BIO.A (H-2a) cells and 6 days later were assayed for cell-mediated cytotoxicity in vitro; also subcutaneous, intraperitoneal, and intrapulmonary tumor neutralization experiments were performed. F1 lymphocytes sensitized by parental cells showed high levels of cytotoxicity to the tumor cells of the parental haplotype but no lysis of parental blastoid cells. Tumor cells from irrelevant haplotypes were also lysed. The cells mediating in this type of killing were characterized phenotypically as Thy-1.2- and Lyt-2.2-positive. In a subcutaneous tumor neutralization test (Winn assay), marked suppression of EL-4 lymphoma (H-2b) and B16 melanoma (H-2b) was observed. Likewise, tumor control was seen in an intraperitoneal tumor model. These studies show that F1 versus parental sensitization can be used to lyse tumor in vitro and in vivo and should be explored as an immunotherapeutic tool.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.